The role of carfilzomib in relapsed/refractory multiple myeloma

被引：17

作者：

Yee, Andrew J. ^{[1
]}

机构：

[1] Harvard Med Sch, Massachusetts Gen Hosp, Canc Ctr, Ctr Multiple Myeloma, 55 Fruit St, Boston, MA 02114 USA

来源：

THERAPEUTIC ADVANCES IN HEMATOLOGY | 2021年 / 12卷

关键词：

carfilzomib; multiple myeloma; PROTEASOME INHIBITOR CARFILZOMIB; ONCE-WEEKLY CARFILZOMIB; LOW-DOSE DEXAMETHASONE; RANDOMIZED PHASE-III; SINGLE-AGENT; IRREVERSIBLE INHIBITOR; SURVIVAL ANALYSIS; SAFETY PROFILE; OPEN-LABEL; BORTEZOMIB;

D O I：

10.1177/20406207211019612

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and as a partner in diverse three drug combinations such as with lenalidomide or daratumumab. While it has an established place in relapsed disease, clinicians should be aware of its cardiovascular and renal adverse event profile, which is manageable, in order to optimize outcomes. This review will provide a perspective on the current and future role of carfilzomib in relapsed/refractory multiple myeloma.

引用

页数：13

共 50 条

[41] Clinical potential of carfilzomib in the treatment of relapsed and refractory multiple myeloma [J].

Gupta, Vikas A. ;

Nooka, Ajay K. ;

Lonial, Sagar ;

Boise, Lawrence H. .

BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2013, 3 :41-51

[42] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma [J].

Xu, Wenjun ;

Sun, Xuedong ;

Wang, Baohong ;

Guo, Hui .

ANNALS OF HEMATOLOGY, 2018, 97 (02) :299-307

[43] Phase I study of carfilzomib, lenalidomide, vorinostat, and dexamethasone in patients with relapsed and/or refractory multiple myeloma [J].

Vesole, David H. ;

Bilotti, Elizabeth ;

Richter, Joshua R. ;

McNeill, Ann ;

McBride, Laura ;

Raucci, Laura ;

Anand, Palka ;

Bednarz, Urszula ;

Ivanovski, Kristin ;

Smith, Judith ;

Batra, Veena ;

Aleman, Adolfo ;

Sims, Taliah ;

Guerrero, Laura ;

Mato, Anthony ;

Siegel, David S. .

BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (01) :52-59

[44] Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study [J].

Kaufman, Jonathan L. ;

Mina, Roberto ;

Jakubowiak, Andrzej J. ;

Zimmermann, Todd L. ;

Wolf, Jeffrey J. ;

Lewis, Colleen ;

Gleason, Charise ;

Sharp, Cathy ;

Martin, Thomas ;

Heffner, Leonard T. ;

Nooka, Ajay K. ;

Harvey, R. Donald ;

Lonial, Sagar .

BLOOD CANCER JOURNAL, 2019, 9 (1)

[45] Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma [J].

Wenjun Xu ;

Xuedong Sun ;

Baohong Wang ;

Hui Guo .

Annals of Hematology, 2018, 97 :299-307

[46] Carfilzomib monotherapy in Japanese patients with relapsed or refractory multiple myeloma: A phase 1/2 study [J].

Iida, Shinsuke ;

Watanabe, Takashi ;

Matsumoto, Morio ;

Suzuki, Kenshi ;

Sunami, Kazutaka ;

Ishida, Tadao ;

Ando, Kiyoshi ;

Chou, Takaaki ;

Ozaki, Shuji ;

Taniwaki, Masafumi ;

Uike, Naokuni ;

Shibayama, Hirohiko ;

Hatake, Kiyohiko ;

Izutsu, Koji ;

Ishikawa, Takayuki ;

Shumiya, Yoshihisa ;

Tobinai, Kensei .

CANCER SCIENCE, 2019, 110 (09) :2924-2932

[47] Outcome of treatment with carfilzomib before and after treatment with daratumumab in relapsed or refractory multiple myeloma patients [J].

Hojholt, Karen Louise ;

Gregersen, Henrik ;

Szabo, Agoston Gyula ;

Klausen, Tobias Wirenfeldt ;

Levring, Mette Boegh ;

Preiss, Birgitte ;

Helleberg, Carsten ;

Breinholt, Marie Fredslund ;

Hermansen, Emil ;

Rahbek Gjerdrum, Lise Mette ;

Bonlokke, Soren Thorgaard ;

Nielsen, Katrine ;

Kjeldsen, Eigil ;

Iversen, Katrine Fladeland ;

Teodorescu, Elena Manuela ;

Kurt, Eva ;

Strandholdt, Casper ;

Andersen, Mette Klarskov ;

Vangsted, Annette Juul .

HEMATOLOGICAL ONCOLOGY, 2021, 39 (04) :521-528

[48] Carfilzomib prescribing patterns and outcomes for relapsed or refractory multiple myeloma: a real-world analysis [J].

Dong, Sharlene ;

Banerjee, Rahul ;

Khan, Adeel M. ;

Wang, Mengru ;

Wang, Xiaoliang ;

Afghahi, Anosheh ;

Afrough, Aimaz ;

Janakiram, Murali ;

Wang, Bo ;

Cowan, Andrew J. ;

Sperling, Adam S. ;

Anderson Jr, Larry D. ;

Rajkumar, S. Vincent ;

Kaur, Gurbakhash .

BLOOD CANCER JOURNAL, 2025, 15 (01)

[49] Cost-effectiveness of carfilzomib plus dexamethasone compared with bortezomib plus dexamethasone for patients with relapsed or refractory multiple myeloma in the United States [J].

Jakubowiak, Andrzej J. ;

Houisse, Ivan ;

Majer, Istvan ;

Benedict, Agnes ;

Campioni, Marco ;

Panjabi, Sumeet ;

Ailawadhi, Sikander .

EXPERT REVIEW OF HEMATOLOGY, 2017, 10 (12) :1107-1119

[50] Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed-refractory Multiple Myeloma in the United States [J].

Pelligra, Christopher G. ;

Parikh, Kejal ;

Guo, Shien ;

Chandler, Conor ;

Mouro, Jorge ;

Abouzaid, Safiya ;

Ailawadhi, Sikander .

CLINICAL THERAPEUTICS, 2017, 39 (10) :1986-2005

← 1 2 3 4 5 →